Human Immunology Biosciences (HI-Bio), a San Francisco, CA-based clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs), raised $95M in Series B funding.
The round was led by Alpha Wave Global with participation from Viking Global Investors, Arkin Bio Capital, Jeito Capital and ARCH Venture Partners.
The company intends to use the funds to advance felzartamab, its clinically differentiated lead therapeutic candidate, through clinical readouts in multiple indications and preparation for registrational studies.
Led by CEO Travis Murdoch, Human Immunology Biosciences, Inc. (HI-Bio™) is a clinical-stage biotechnology company focused on discovering and developing precision medicines for people suffering from immune-mediated diseases (IMDs). Since the launch, HI-Bio has advanced felzartamab, a monoclonal antibody targeting CD38 and in-licensed from MorphoSys, across indications including antibody-mediated rejection (AMR), IgA nephropathy (IgAN), lupus nephritis (LN) and primary membranous nephropathy (PMN). Felzartamab has received Breakthrough Therapy Designation and Orphan Drug Designation from the U.S. Food and Drug Administration in PMN. HI-Bio has also initiated a clinical study of HIB210, an anti-C5aR1 candidate targeting neutrophil activation and chemotaxis.
FinSMEs
04/01/2024